Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy

Bibliography

• Garrison FH. History of neurology. Revised and enlarged by McHenry LC Jr. Charles C Thomas Publishing, Springfield, III; 1969
   Google Scholar
• Lopez AD, Mathers CD, Ezzati M, Global and regional burden of disease and disk factors, 2001: systematic analysis of population health data. Lancet 2006;6:1747-57
   Google Scholar
• Bravata DM, Ho SY, Meehan TP, Readmission and death after hospitalization for acute ischemic stroke: 5-year follow-up in the medicare population. Stroke 2007;38:1899-904
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics- 2010 Update: a report from the American Heart Association. Circulation 2010;121:948-54
   PubMed Web of Science ®Google Scholar
• Wolfe T, Suarez JI, Tarr RW, Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke. J Stroke Cerebrovasc Dis 2008;17:121-8
   PubMedGoogle Scholar
• Jung KT, Shin DW, Lee KJ, Oh M. Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review. J Clin Neurol 2010;6(3):117-26
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurolgical Disorders and Stroke rt-Pa Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7
   PubMed Web of Science ®Google Scholar
• Lees KR, Bluhmki E, von Kummer R, Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-703
   PubMed Web of Science ®Google Scholar
• Diener HC, Ringelstein EB, Von Kummer R, Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Stroke 2001;32:22-9
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, ; for the ECASS study group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25
   PubMed Web of Science ®Google Scholar
• Nakahima T, Minematsu K. Prospects of thrombolytic therapy for acute ischemic stroke. Brain Nerve 2009;61:1003-12
   PubMedGoogle Scholar
• Hacke W, Kaste M, Bluhmki E, ; for the ECASS Investigators. Thrombolysis with Alteplase 3 to 4,5 hours after Acute ischemic stroke. N Engl J Med 2008;359:1317-29
   PubMed Web of Science ®Google Scholar
• Ahmed N, Wahlgren N, Hennerici MGM, ; for the SITS investigators. Implementation and outcome of thrombolysis with alteplase 3-4,5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet 2010; DOI:10.1016/S1474-4422(10)70165-4
   Google Scholar
• Molina C, Saver JL. Extending reperfusion therapy for acute ischemic stroke. Emerging pharmacological, mechanical, and imaging strategies. Stroke 2005;36:2311-20
   PubMed Web of Science ®Google Scholar
• Berger C, Fiorelli M, Steiner T, Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001;32:1330-5
   PubMed Web of Science ®Google Scholar
• del Zoppo GJ, Higashida RT, Furlan AJ, PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke—PROACT Investigators. Prolyse in acute cerebral thromboembolism. Stroke 1998;29:4-11
   PubMed Web of Science ®Google Scholar
• Saqqur M, Tsivgoulis G, Molina CA, ; CLOTBUST-PRO Investigators. Design of a PROspective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO). Int J Stroke 2008;3(1):66-72
   PubMed Web of Science ®Google Scholar
• Alexandrov AV, Wojner AW, Grotta JC, Clotbust Investigators. CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. J Neuroimaging 2004;14(2):108-12
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, Cyclooxygenase inhibitors and the antiplatelt effects of aspirin. N Engl J Med 2001;345:1809-17
   PubMed Web of Science ®Google Scholar
• CAPRIE Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39
   PubMedGoogle Scholar
• Srivastava P. Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention. Ann Indian Acad Neurol 2010;13:6-13
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischemic stroke and transient ischemic attack to prevent recurrent major vascular events. Lancet Neurol 2010;9:273-84
   PubMed Web of Science ®Google Scholar
• Gent M, Blakely JA, Easton JD, The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results. Stroke 1988;19:1203-10
   PubMed Web of Science ®Google Scholar
• Pryse-Phillips W. Ticlopidine aspirin stroke study: outcome by vascular distribution of the qualifying event. J Stroke Cerebrovasc Dis 1993;3:49-56
   Google Scholar
• Gorelick P, Richardson D, Kelly M, ; African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trila. JAMA 2003;289:2947-57
   PubMed Web of Science ®Google Scholar
• Diener H, Cunha L, Forbes C, European Stroke Prevention Study. 2. Dipirydamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13
   PubMed Web of Science ®Google Scholar
• Fillippi A. ESPRIT trial. Lancet 2006;368:447-8
   Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Bogousslavsky J. Primary and secondary prevention of ischemic stroke. Eur Neurol 2010;63:267-78
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Warfarin-aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic stroke? Stroke 2002;33:1723-6
   PubMed Web of Science ®Google Scholar
• ACTIVE Writing Group. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Pajitnev D, Pogue J, ; ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007;50:2156-61
   PubMed Web of Science ®Google Scholar
• Ariesen MF, Algra A, Kappelle LJ. Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 2006;37:134. 138
   Google Scholar
• Halkes PH, van Gijn J, Kappelle LJ, ; ESPRIT Study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2007;367:1665-73
   Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, ; Clopidogrel in Unstable Angina to prevent recurrent events trial investigators. Clopidogrel in unstable angina to prevent recurrent events (CURE) trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;245:494-502
   Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, ; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, ; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607-21
   PubMed Web of Science ®Google Scholar
• Diener HC, Bogousslavsky J, Brass LM, ; on behalf of the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blinded, placebo-controlled trial. Lancet 2004;364:331-7
   PubMed Web of Science ®Google Scholar
• Hermosillo AJ, Spinler SA. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? Ann Pharmacother 2008;42:790-805
   PubMed Web of Science ®Google Scholar
• Kennedy J, Hill MD, Ryckborst KJ, ; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007;6(11):961-9
   PubMed Web of Science ®Google Scholar
• Philip MW, Cotton D, Martin RH, ; for the PRoFESS Study Group. Effect of combined aspirin and extended-realease Dipyridamole versus Clopidogrel on functional outcome and recurrence in acute ischemic stroke. PRoFESS Subgroup Analysis. Stroke 2010;41:732-8
   PubMed Web of Science ®Google Scholar
• The Abciximab in Ischmic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000;31:601-9
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Sthle H, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303
   PubMed Web of Science ®Google Scholar
• Hennerici MG, PERFORM Study Investigators. Rationale and design of the prevention of cerebrovascular and vardiovscuar events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc Dis 2009;27(Suppl 3):28-32
   PubMedGoogle Scholar
• Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010;196:407-18
   PubMedGoogle Scholar
• Diener HC. Executive Steering Committee of SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006;21:279-93
   PubMed Web of Science ®Google Scholar
• Lip G, Rasmussen L, Olsson SB, Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009;23:2897-907
   Google Scholar
• Bousser MG, Bouthier J, Buller HR, ; Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thrombembolism in patients with atrial fibrillation: a randomised, open-label non-inferiority trial. Lancet 2008;371:315-21
   PubMed Web of Science ®Google Scholar
• Sallustio F, Totondo F, Di Legge S, Stanzione P. Cliostazol in the management of atherosclerosis. Curr Vasc Pharmacol 2010;8:363-72
   PubMed Web of Science ®Google Scholar
• Huang Y, Cheng Y, Wu J, ; Cliostazol versus Aspirin for Secondaary Ischaemic Stroke Prevention cooperation investigators. Cliostazol as an alternative to aspirin after ishaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008;7:494-9
   PubMed Web of Science ®Google Scholar
• Guo JJ, Xu E, Lin QY, Effect of cliostazol on cerebral arteries in secondary prevention of ischemic stroke. Neurosci Bull 2009;25:383-90
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64(3):292-303
   PubMed Web of Science ®Google Scholar
• Maegdefessel L, Spin JM, Azuma J, Tsao PS. New options with dabigatran etexilate in anticoagulant therapy. Vasc Health Risk Manag 2010;6:339-49
   PubMedGoogle Scholar
• Conolly SJ, Ezekowitz MD, Yusuf S, ; the RELY Steering Committee and Invesigators. Dabigatran versus Warfarin in Patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Piccini JP, Lopes RD, Mahaffey KW. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol 2010;25:312-20
   PubMed Web of Science ®Google Scholar
• Turpie AG. Oral direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arteriorscler Trhomb Vasc Biol 2007;27:1238-47
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Xin B, Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and anthihemostatic studies. J Thromb Haemost 2008;6:820-9
   PubMed Web of Science ®Google Scholar
• APRAISE Steering Committee and Investigators. Apixaban, an oral direct selective factor Xa inhibitor in combination with antiplatelet therapy after acute coronary syndrome. Results of the Apixaban for Prevention of Acute ischemic and safety events (APRAISE) Trial. Circulation 2009;119:2877-85
   PubMed Web of Science ®Google Scholar
• Lopes RD, Alexander JH, Al-Khatib SM, ; on bhalf of the ARISTOTLE Investigators. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331. 339
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. Apixaban versus acetylsalicylic acid (ASA) to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment: a randomized double blind. Available from: http://clinicaltrials.gov/ct2/show/NCT00496769
   Google Scholar
• Weitz JI, Connolly SJ, Kunitada S, Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation. ASH Annual Meeting; San Francisco; 2008
   Google Scholar
• U.S. National Institutes of Health. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation – effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE - AF TIMI - 48). Available from: http://clinicaltrials.gov/ct2/show/NCT00781391
   Google Scholar
• The Executiv Steering Committee on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroe and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-7
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, ; on behalf of the ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Turpie AG, Lassen MR, ; ONYX study group. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007;5:1660-5
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. A phase 2, double-blind, double-dummy, randomized, parallel group dose finding study to investigate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation and to compare the safety and tolerability with warfarin. Available from: http://clinicaltrials.gov/ct2/show/NCT00938730?term=YM150&rank=8
   Google Scholar
• Schiele F. Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. Vasc Health Risk Manag 2010;6:179-87
   PubMedGoogle Scholar
• Anderson JA, Hirsh J, Yusuf S, Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. J Thromb Haemost 2010;8(2):243-9
   PubMed Web of Science ®Google Scholar
• The OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295
   Google Scholar
• Harenberg J. Development of idraparinux and idraiotaparinux for anticoagulant therapy. Thromb Haemost 2009;102:811-15
   PubMed Web of Science ®Google Scholar
• Sobieraj-Teague M, O'Donnel M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009;35:515-24
   PubMed Web of Science ®Google Scholar
• Weitz JI. Potential of new anticoagulants in patients with cancer. Thromb Res 2010;125:S30-35
   PubMed Web of Science ®Google Scholar
• Abbate R, Crea F, De Servi S, Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel. G Ital Caardiol 2010;11:127-37
   PubMedGoogle Scholar
• Wiviott SD, Braunwald E, McCabe CH, ; for the TRITON–TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Anderson SD, Shah NK, Yim J, Epstein BJ. Efficacy and safety of Ticagrelor: a reversible P2Y12 receptor antagonist. Ann Pharmacother 2010;44:524-37
   PubMed Web of Science ®Google Scholar
• Doggrell SA. Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes. IDrugs 2009;12:309-17
   PubMed Web of Science ®Google Scholar
• Sacco R, Chong JY, Prabhakaran S, Elkind MSV. Exprimental treatments for acute ischemic stroke. Lancet 2007;639:331-41
   Google Scholar
• Hacke W, Albers G, Al-Rawi Y, ; for The DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke trial (DIAS). A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. A randomised, double-blind, parallel-group placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke. Available from: http://clinicaltrials.gov/ct2/show/NCT00790920
   Google Scholar
• U.S. National Institutes of Health. A randomised, double-blind, parallel-group placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke. Available from: http://clinicaltrials.gov/ct2/show/NCT00856661?term=dias+4&rank=1
   Google Scholar
• Haley EC, Thompson JL, Grotta JC, ; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010;41(4):707-11
   PubMed Web of Science ®Google Scholar
• Levy DE, Trammel J, Wasiewski WW, Ancrod Stroke Program (ASP) Study Team. Ancrod for acute ischemic stroke: a new dosing regimen derived from analysis of prior ancrod stroke studies. J Stroke Cerebrovasc Dis 2009;18(1):23-7
   PubMed Web of Science ®Google Scholar
• Levy DE, del Zoppo GJ, Demaerschalk BM, Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke 2009;40(12):3796-803
   PubMed Web of Science ®Google Scholar
• Guo Y, Zuo YF, Wang QZ, Meta-analysis of defibrase in treatment of acute cerebral infarction. Chin Med J (Engl) 2006;119(8):662-8
   PubMed Web of Science ®Google Scholar
• Xu G, Liu X, Zhu W, Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention. Blood Coagul Fibrinolysis 2007;18(2):193-7
   PubMed Web of Science ®Google Scholar
• Park JS, Park SS, Koh EJ, Treatment for patients with acute ischemic stroke presenting beyond six hours of ischemic symptom onset: effectiveness of intravenous direct thrombin inhibitor, argatroban. J Korean Neurosurg Soc 2010;47(4):258-64
   PubMed Web of Science ®Google Scholar
• Kleinschnitz C, Pozgajova M, Pham M, Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007;115(17):2323-30
   PubMed Web of Science ®Google Scholar
• Cortese B, Micheli A, Picchi A, Limbruno U. Combined, superselective pharmacological management of large coronary thrombus burden. J Invasive Cardiol 2009;21(4):168-71
   PubMed Web of Science ®Google Scholar
• Pancioli AM, Broderick J, Brott T, ; CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008;39(12):3268-76
   PubMed Web of Science ®Google Scholar
• Post JM, Alexander S, Wang YX, Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res 2008;122(4):533-40
   PubMed Web of Science ®Google Scholar
• Mpri K, Kikuchi H, Obara Y, Inhibitory effect of herivenone B from Hericium erinaceus on collagen-induced platelet aggregation. Phytomedicine 2010, doi:10.1016/j.phymed.2010.05.004
   Google Scholar